Aclaris Therapeutics Inc (ACRS)

03:11 AM

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co. - Defense World

03:11 AM

May 01, 2025

Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo

May 01, 2025

Apr 30, 2025

Geode Capital Management LLC Reduces Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 30, 2025

Apr 30, 2025

XTX Topco Ltd Acquires New Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 30, 2025

Apr 30, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 34.8% in April - Defense World

Apr 30, 2025

Apr 29, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 29, 2025

Apr 29, 2025

Aclaris Therapeutics Names Jesse Hall Chief Medical Officer - marketscreener.com

Apr 29, 2025

Apr 29, 2025

Aclaris Therapeutics (ACRS) Welcomes Jesse Hall as Chief Medical Officer | ACRS Stock News - GuruFocus

Apr 29, 2025

Apr 29, 2025

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - marketscreener.com

Apr 29, 2025

Apr 29, 2025

Aclaris Therapeutics appoints new Chief Medical Officer - Investing.com

Apr 29, 2025

Apr 29, 2025

Aclaris Strengthens Leadership: Humira and Prolia Developer Takes CMO Role to Advance Immunology Pipeline - Stock Titan

Apr 29, 2025

Apr 29, 2025

Androgenetic Alopecia Treatment Market Generated - openPR.com

Apr 29, 2025

Apr 26, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.67 Average Target Price from Brokerages - Defense World

Apr 26, 2025

Apr 25, 2025

Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance

Apr 25, 2025

Apr 24, 2025

Aclaris Therapeutics Inc [ACRS] Records 50-Day SMA of $1.6630 - knoxdaily.com

Apr 24, 2025

Apr 24, 2025

The time has not yet come to remove your chips from the table: Aclaris Therapeutics Inc (ACRS) - Sete News

Apr 24, 2025

Apr 23, 2025

Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN

Apr 23, 2025

Apr 23, 2025

Trading Day Triumph: Aclaris Therapeutics Inc (ACRS) Ends at 1.10, a -2.65 Surge/Plunge - DWinneX

Apr 23, 2025

Apr 23, 2025

Some Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shareholders Look For Exit As Shares Take 31% Pounding - simplywall.st

Apr 23, 2025

Apr 23, 2025

Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052 - Yahoo Finance

Apr 23, 2025

Apr 23, 2025

FDA clears Aclaris’ new drug for clinical trial - Investing.com Australia

Apr 23, 2025

Apr 22, 2025

FDA clears Aclaris’ new drug for clinical trial By Investing.com - Investing.com South Africa

Apr 22, 2025

Apr 22, 2025

ACRS’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com

Apr 22, 2025

Apr 22, 2025

Aclaris Therapeutics gets FDA nod to begin trial of ATI-052 - MSN

Apr 22, 2025

Apr 22, 2025

Aclaris Gets FDA Clearance for Clinical Trial of Immuno-Inflammatory Treatment - marketscreener.com

Apr 22, 2025

Apr 22, 2025

Aclaris Therapeutics (ACRS) Gains on FDA Clearance for ATI-052 Trial - GuruFocus

Apr 22, 2025

Apr 22, 2025

Aclaris gets FDA nod to begin trial of ATI-052 (ACRS:NASDAQ) - Seeking Alpha

Apr 22, 2025

Apr 22, 2025

Aclaris Therapeutics Shares Rise After FDA Clear ATI-052 for Trial - marketscreener.com

Apr 22, 2025

Apr 22, 2025

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody - The Manila Times

Apr 22, 2025

Apr 22, 2025

Aclaris Therapeutics (ACRS) Gains FDA Clearance for Novel Antibody Trial | ACRS Stock News - GuruFocus

Apr 22, 2025

Apr 22, 2025

Aclaris Therapeutics Secures U.S. Food and Drug - GlobeNewswire

Apr 22, 2025

Apr 22, 2025

Aclaris Therapeutics (ACRS) Gains on FDA Clearance for ATI-052 T - GuruFocus

Apr 22, 2025

Apr 14, 2025

Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com

Apr 14, 2025

Apr 14, 2025

Arthralgia Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis - The Globe and Mail

Apr 14, 2025

Apr 12, 2025

Commonwealth Equity Services LLC Buys New Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 12, 2025

Apr 11, 2025

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN

Apr 11, 2025

Apr 10, 2025

Aclaris Therapeutics Inc (ACRS) Has Recovered 21.49% From Its Low: Is This The Beginning Of A Trend? - Stocksregister

Apr 10, 2025

Apr 10, 2025

Aclaris Therapeutics Inc [ACRS] Director makes an insider purchase of 666,666 shares worth 1.5 million. - knoxdaily.com

Apr 10, 2025

Apr 09, 2025

Raymond James Financial Inc. Acquires Shares of 154,351 Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 09, 2025

Apr 05, 2025

Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st

Apr 05, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 02, 2025

Apr 01, 2025

Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.67 - Defense World

Apr 01, 2025

Apr 01, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - Defense World

Apr 01, 2025

Mar 31, 2025

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Yahoo Finance

Mar 31, 2025

Mar 29, 2025

HighTower Advisors LLC Has $652,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Mar 29, 2025

Mar 27, 2025

Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases - Investing.com India

Mar 27, 2025